Ipsen gains licence to develop mesdopetam

Ipsen has gained exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist, from IRLAB.

Mesdopetam is being assessed in Phase IIb clinical trials as a potential treatment option for people living with Parkinson’s disease (PD) experiencing levodopa-induced dyskinesia (LID).

Mesdopetam has also shown antipsychotic properties in preclinical studies.

“By working in partnership, we aim to bring investigational mesdopetam to people living with Parkinson’s disease experiencing levodopa-induced dyskinesia,” said Dr Howard Mayer, Executive Vice President and Head of Research and Development at Ipsen.

“We are delighted to strengthen our pipeline and deepen our commitment to the neuroscience community around the world, including to patients living with this debilitating neurodegenerative disorder.”

Under the terms of the agreement, IRLAB will be eligible to receive up to $363 million, including an upfront cash payment of $28 million and up to $335 million in development, regulatory and commercial milestones.

IRLAB is also eligible to receive tiered low double-digit royalties on worldwide net sales of mesdopetam.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news